Ofloxacin

Ofloxacin is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone. The original brand, Floxin, has been discontinued by the manufacturer in the United States on 18 June 2009, though generic equivalents continue to be available.

Ofloxacin was first patented in 1982 (European Patent Daiichi) and received approval from the U.S. Food and Drug Administration (FDA) on December 28, 1990. Ofloxacin is sold under a wide variety of brand names as well as generic drug equivalents, for oral and intravenous administration. Ofloxacin is also available for topical use, as eye drops and ear drops (marketed as Ocuflox and Floxin Otic respectively in the United States).

Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin. When levofloxacin disks were not available in early clinical trials, a 5-pg ofloxacin disk was substituted. The U.S. Food and Drug Administration (FDA) medical reviewers considered the two drugs to be one and the same and hence interchangeable.

Like other quinolones, ofloxacin has been associated with a significant number of serious adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); such reactions may manifest long after therapy had been completed, and, in severe cases, may result in lifelong disabilities. Ofloxacin has also been associated with severe psychiatric adverse reactions.

Hepatotoxicity has also been reported with the use of ofloxacin. Case reports of hepatitis have been published for the older fluoroquinolones including ciprofloxacin, ofloxacin, and norfloxacin.

Read more about Ofloxacin:  History, Medical Uses, Available Forms, Mode of Action, Contraindications, Adverse Effects, Interactions, Overdose, Pharmacology, Pharmacokinetics, Dosage, Susceptible Bacteria, Additional Regulatory History, Antibiotic Abuse and Bacterial Resistance, Current Litigation, Package Insert Links

Other articles related to "ofloxacin":

Ofus
... Ofloxacin is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone ... Ofloxacin was first patented in 1982 (European Patent Daiichi) and received approval from the U.S ... Ofloxacin is sold under a wide variety of brand names as well as generic drug equivalents, for oral and intravenous administration ...
Ofus - Antibiotic Abuse and Bacterial Resistance
... See also Antibiotic abuse and Antibiotic resistance Resistance to ofloxacin and other fluoroquinolones may evolve rapidly, even during a course of ... Years ago the FDA had added warnings regarding the proper use of ofloxacin within the package insert to combat such antibiotic abuse, advising physicians that ofloxacin ... Normally ofloxacin should only be used in patients who have failed at least one prior therapy ...
Ofus - Current Litigation
... The manufacturers (Johnson and Johnson/Ortho McNeil) of ofloxacin are currently embroiled in litigation concerning levofloxacin/ofloxacin in regards to spontaneous tendon ruptures ... Such ruptures have also been associated with ofloxacin, as well as other drugs found within this class ... product liability suits involving levofloxacin/ofloxacin ...
Ofus - Pharmacokinetics
... Ofloxacin has been detected in blister fluid, cervix, lung tissue, ovary, prostatic fluid, prostatic tissue, skin, and sputum ... of the endogenous compounds that have been reported to be affected by ofloxacin as inhibitors, alteraters and depletors ... See the latest package insert for Ofloxacin for additional details ...
Ofloxacin - Package Insert Links
... Floxin (Ofloxacin -- Floxacin) Package Insert Levaquin Package Insert. ...